Suppr超能文献

PSMD4是一种在由Nrf2的细胞质定位激活的化疗耐药性结直肠癌中的新型治疗靶点。

PSMD4 is a novel therapeutic target in chemoresistant colorectal cancer activated by cytoplasmic localization of Nrf2.

作者信息

Cheng Ya-Min, Lin Po-Lin, Wu De-Wei, Wang Lee, Huang Chi-Chou, Lee Huei

机构信息

Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei, Taiwan.

出版信息

Oncotarget. 2018 May 29;9(41):26342-26352. doi: 10.18632/oncotarget.25254.

Abstract

UNLABELLED

Nuclear Nrf2 (nNrf2) binding to the antioxidant response element may promote chemoresistance in colorectal cancer. However, the shuttling of Nrf2 between cytoplasm and nucleus in colon cancer cells has revealed the possibility that cytoplasmic location of Nrf2 (cNrf2) may play a specific role in chemoresistance. Transfection of a nuclear location sequence (NLS)-wild-type or NLS-mutated Nrf2 expression vector into a stable shNrf2 HCT116 clone using the MTT assay to examine whether chemoresistance induced by cNrf2 may be greater than nNrf2. Different specific inhibitors and small hairpin (sh)RNAs of targeting genes were used to verify the mechanistic action of cNrf2 in chemoresistance and further confirmed by an animal model. The association of cNrf2 with chemotherapeutic response in patients with colorectal cancer was statistically analyzed. The MTT assay indicated that cNrf2 may play a more important role than nNrf2 in conferring 5-fluorouracil (5-FU) and oxaliplatin resistance in HCT116 cells. Mechanistically, cNrf2-induced PSMD4 expression was responsible for chemoresistance in the NLS-mutated Nrf2-tranfected shNrf2HCT116 clone via the NF-κB/AKT/β-catenin/ZEB1 cascades. The tumor burden induced by the NLS-mutated Nrf2-transfected shNrf2HCT116 clone was completely suppressed by treatment with 5-FU in combination with carfilzomib. A higher prevalence of unfavorable chemotherapeutic response in colorectal cancer patients with cNrf2, PSMD4-positive, p-p65-positive, and nuclear β-catenin tumors was observed when compared to their counterparts. cNrf2 may play a more important role than nNrf2 in the chemoresistance of colorectal cancer. Activation of the NF-κB/AKT/β-catenin/ZEB1 cascade by PSMD4 may be responsible for cNrf2-mediated chemoresistance.

CONDENSED ABSTRACT

CNrf2 may play a more important role than nNrf2 in conferring 5-FU and oxaliplatin resistance. This observation in patients seemed to support the findings of the cell and animal models and suggested that PSMD4 may be responsible cNrf2-mediated chemoresistance via the NF-κB/AKT/β-catenin /ZEB1 cascades.

摘要

未标记

细胞核中的核因子E2相关因子2(nNrf2)与抗氧化反应元件结合可能会促进结直肠癌的化疗耐药性。然而,Nrf2在结肠癌细胞的细胞质和细胞核之间穿梭表明,Nrf2的细胞质定位(cNrf2)可能在化疗耐药中发挥特定作用。使用MTT试验将核定位序列(NLS)-野生型或NLS-突变的Nrf2表达载体转染到稳定的shNrf2 HCT116克隆中,以检查cNrf2诱导的化疗耐药性是否可能大于nNrf2。使用不同的靶向基因特异性抑制剂和小发夹(sh)RNA来验证cNrf2在化疗耐药中的作用机制,并通过动物模型进一步证实。对结直肠癌患者中cNrf2与化疗反应的相关性进行了统计分析。MTT试验表明,在赋予HCT116细胞5-氟尿嘧啶(5-FU)和奥沙利铂耐药性方面,cNrf2可能比nNrf2发挥更重要的作用。从机制上讲,cNrf2诱导的蛋白酶体26S亚基非ATP酶调节因子4(PSMD4)表达通过核因子κB(NF-κB)/蛋白激酶B(AKT)/β-连环蛋白/ZEB1级联反应导致NLS-突变的Nrf2转染的shNrf2HCT116克隆产生化疗耐药性。用5-FU联合卡非佐米治疗可完全抑制NLS-突变的Nrf2转染的shNrf2HCT克隆诱导的肿瘤负荷。与相应患者相比,cNrf2、PSMD4阳性、磷酸化p65阳性和细胞核β-连环蛋白肿瘤的结直肠癌患者中不良化疗反应的发生率更高。在结直肠癌的化疗耐药中,cNrf2可能比nNrf2发挥更重要的作用。PSMD4激活NF-κB/AKT/β-连环蛋白/ZEB1级联反应可能是cNrf2介导的化疗耐药的原因。

摘要

在赋予5-FU和奥沙利铂耐药性方面,cNrf2可能比nNrf2发挥更重要的作用。患者中的这一观察结果似乎支持细胞和动物模型的研究结果,并表明PSMD4可能是cNrf2通过NF-κB/AKT/β-连环蛋白/ZEB1级联反应介导化疗耐药的原因。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c73/5995171/14608b71653b/oncotarget-09-26342-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验